Trump Administration Considers Marijuana Rescheduling Amid Internal Debate

President Donald Trump's administration is reconsidering federal marijuana policy, including the possibility of reclassifying cannabis from a Schedule I to a Schedule III drug, which would reduce restrictions and potentially expand medical research and tax benefits. During a recent $1 million-a-plate fundraiser at his Bedminster golf club, Trump indicated that marijuana reform is under review, reflecting divisions within his administration between advisors who support rescheduling to fulfill campaign promises and those cautioning about political risks. White House Chief of Staff Susie Wiles has gathered input from federal agencies into a report currently under review, while the administration emphasizes that its decisions will prioritize the American people's best interests. The marijuana industry has financially supported Trump's political efforts, including significant donations to his super PAC, highlighting the sector's vested interest in federal reform. Despite Trump's prior campaign support for easing marijuana restrictions and backing legalization initiatives, he has remained largely silent on the issue since starting his second term. With marijuana legalized for medical or recreational use in most U.S. states, the administration's forthcoming policy stance is being closely watched by advocates and industry leaders.